Search results
Results from the WOW.Com Content Network
Interferon beta-1b is a cytokine in the interferon family used to ... Skin reactions are more prevalent in women. [2] ... Side effects are often onerous enough that ...
One of the major limiting factors in the efficacy of type I interferon therapy are the high rates of side effects. Between 15% - 40% of people undergoing type 1 IFN treatment develop major depressive disorders. [18] Less commonly, interferon treatment has also been associated with anxiety, lethargy, psychosis and parkinsonism. [19]
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). [5] It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. [6] Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. [7]
Scientists have known for many years that people with lupus have excess amounts of type I interferon — but the new study links this issue to several negative effects. First, too much type I ...
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [4] [5]The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. [3] [4] For hepatitis B it may be used alone. [5] It is given by injection under the skin. [3] Side effects ...
In 1993, interferon beta-1b was the first drug to ever be approved for MS, being soon followed by interferon beta-1a and glatiramer acetate. [ 25 ] Interferon beta-1a is injected either weekly ( intramuscular injection ) or three times a week ( subcutaneous injection ) depending on commercial formulations, [ 26 ] [ 27 ] while interferon beta-1b ...
[3] [6] Ropeginterferon alfa-2b is the first medication approved by the US Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. [3] The FDA considers it to be a first-in-class medication. [7]